Physician profile
Mark Andrew Cedar
NPI 1629053053
$2,716.19
in general payments reported to CMS, 2019-2025
17 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $231 · 2021: $179 · 2022: $573 · 2023: $592 · 2024: $340 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.22 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Medtronic, INC. | $419.38 | 2021-2025 | Endoflip, Barrx, Interstim |
| Janssen Biotech, INC. | $412.02 | 2020-2025 | Stelara, Tremfya |
| Medtronic USA, INC. | $334.34 | 2019-2020 | |
| Covidien LP | $173.83 | 2019-2020 | |
| Boston Scientific Corporation | $171.25 | 2019-2023 | Spyglass |
| Celgene Corporation | $84.84 | 2022-2023 | Zeposia |
| Genzyme Corporation | $73.40 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $55.99 | 2022-2023 | Dupixent |
| Braintree Laboratories, INC. | $51.41 | 2022-2025 | Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.68 | 2023 | Xifaxan |
| Pfizer INC. | $45.60 | 2023-2024 | |
| Daiichi Sankyo INC. | $28.68 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.54 | 2023 | Rebyota |
| Conmed Corporation | $18.88 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $18.87 | 2023 | Linzess |
| Astrazeneca Pharmaceuticals LP | $14.26 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cedar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.